These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26536508)

  • 1. Using Australian Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: challenges and approaches.
    Page E; Kemp-Casey A; Korda R; Banks E
    Public Health Res Pract; 2015 Sep; 25(4):e2541546. PubMed ID: 26536508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers.
    Mellish L; Karanges EA; Litchfield MJ; Schaffer AL; Blanch B; Daniels BJ; Segrave A; Pearson SA
    BMC Res Notes; 2015 Nov; 8():634. PubMed ID: 26526064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies using Australia's Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987-2013).
    Pearson SA; Pesa N; Langton JM; Drew A; Faedo M; Robertson J
    Pharmacoepidemiol Drug Saf; 2015 May; 24(5):447-55. PubMed ID: 25833702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Aust N Z J Public Health; 2009 Jun; 33(3):246-52. PubMed ID: 19630844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing face of Australian data reforms: impact on pharmacoepidemiology research.
    de Oliveira Costa J; Bruno C; Schaffer AL; Raichand S; Karanges EA; Pearson SA
    Int J Popul Data Sci; 2021 Apr; 6(1):1418. PubMed ID: 34007904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacoepidemiolgy: regulatory basis, methodological approaches and scope].
    Ahid S; Belaguide K; Cherrah Y
    East Mediterr Health J; 2012 Jan; 18(1):85-93. PubMed ID: 22360016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guidelines for good database selection and use in pharmacoepidemiology research.
    Hall GC; Sauer B; Bourke A; Brown JS; Reynolds MW; LoCasale R
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):1-10. PubMed ID: 22069180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Future Perspective of Pharmacoepidemiology in the "Big Data Era" and the Growth of Information Sources].
    Macías Saint-Gerons D; de la Fuente Honrubia C; de Andrés Trelles F; Catalá-López F
    Rev Esp Salud Publica; 2016 Dec; 90():e1-e7. PubMed ID: 27905352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial contributions made by patients towards dispensed medicines prescribed by Australian dentists from 2006 to 2018: a cost-analysis study.
    Park JS; Kruger E; Tennant M
    Aust Health Rev; 2021 Mar; 45(2):167-172. PubMed ID: 33176901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A data-informed approach using individualised dispensing patterns to estimate medicine exposure periods and dose from pharmaceutical claims data.
    Bharat C; Degenhardt L; Pearson SA; Buizen L; Wilson A; Dobbins T; Gisev N
    Pharmacoepidemiol Drug Saf; 2023 Mar; 32(3):352-365. PubMed ID: 36345837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoepidemiology--an Irish perspective.
    Williams D; Feely J
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):641-5. PubMed ID: 11980254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoepidemiological safety studies in children: a systematic review.
    Osokogu OU; Dukanovic J; Ferrajolo C; Dodd C; Pacurariu AC; Bramer WM; 'tJong G; Weibel D; Sturkenboom MC; Kaguelidou F
    Pharmacoepidemiol Drug Saf; 2016 Aug; 25(8):861-70. PubMed ID: 27255559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Pharmaceutical Benefits Scheme and implications for paediatric prescribing.
    Sinha Y; Brien JA; Craig JC
    J Paediatr Child Health; 2009 Jun; 45(6):351-7. PubMed ID: 19490409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoepidemiology research: delivering evidence about drug safety and effectiveness in mental health.
    Davis KAS; Farooq S; Hayes JF; John A; Lee W; MacCabe JH; McIntosh A; Osborn DPJ; Stewart RJ; Woelbert E
    Lancet Psychiatry; 2020 Apr; 7(4):363-370. PubMed ID: 31780306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review.
    Gault N; Castañeda-Sanabria J; Guillo S; Foulon S; Tubach F
    Pharmacoepidemiol Drug Saf; 2016 Apr; 25(4):372-7. PubMed ID: 26781227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of self-controlled designs in pharmacoepidemiology.
    Hallas J; Pottegård A
    J Intern Med; 2014 Jun; 275(6):581-9. PubMed ID: 24635348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Nordic countries as a cohort for pharmacoepidemiological research.
    Furu K; Wettermark B; Andersen M; Martikainen JE; Almarsdottir AB; Sørensen HT
    Basic Clin Pharmacol Toxicol; 2010 Feb; 106(2):86-94. PubMed ID: 19961477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Translation and introduction of Guide to Methodological Standards in Pharmacoepidemiology].
    Tian F; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2949-57. PubMed ID: 24471310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immortal time bias in pharmacoepidemiological studies: definition, solutions and examples].
    Faillie JL; Suissa S
    Therapie; 2015; 70(3):259-63. PubMed ID: 25487848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.